HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel mRNA therapy restores GALT protein and enzyme activity in a zebrafish model of classic galactosemia.

Abstract
Messenger RNA (mRNA) has emerged as a novel therapeutic approach for inborn errors of metabolism. Classic galactosemia (CG) is an inborn error of galactose metabolism caused by a severe deficiency of galactose-1-phosphate:uridylyltransferase (GALT) activity leading to neonatal illness and chronic impairments affecting the brain and female gonads. In this proof of concept study, we used our zebrafish model for CG to evaluate the potential of human GALT mRNA (hGALT mRNA) packaged in two different lipid nanoparticles to restore GALT expression and activity at early stages of development. Both one cell-stage and intravenous single-dose injections resulted in hGALT protein expression and enzyme activity in the CG zebrafish (galt knockout) at 5 days post fertilization (dpf). Moreover, the levels of galactose-1-phosphate (Gal-1-P) and galactonate, metabolites that accumulate because of the deficiency, showed a decreasing trend. LNP-packaged mRNA was effectively translated and processed in the CG zebrafish without signs of toxicity. This study shows that mRNA therapy restores GALT protein and enzyme activity in the CG zebrafish model, and that the zebrafish is a suitable system to test this approach. Further studies are warranted to assess whether repeated injections safely mitigate the chronic impairments of this disease.
AuthorsBritt Delnoy, Minela Haskovic, Jo Vanoevelen, Laura K M Steinbusch, Esther Naomi Vos, Kèvin Knoops, Luc J I Zimmermann, Marek Noga, Dirk J Lefeber, Paolo G V Martini, Ana I Coelho, Maria Estela Rubio-Gozalbo
JournalJournal of inherited metabolic disease (J Inherit Metab Dis) Vol. 45 Issue 4 Pg. 748-758 (07 2022) ISSN: 1573-2665 [Electronic] United States
PMID35527402 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2022 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Chemical References
  • Lipid Nanoparticles
  • Liposomes
  • RNA, Messenger
  • Nucleotidyltransferases
  • UTP-Hexose-1-Phosphate Uridylyltransferase
  • Galactose
Topics
  • Animals
  • Female
  • Galactose (metabolism)
  • Galactosemias (diagnosis, genetics, therapy)
  • Humans
  • Infant, Newborn
  • Liposomes
  • Nanoparticles
  • Nucleotidyltransferases
  • RNA, Messenger (genetics)
  • UTP-Hexose-1-Phosphate Uridylyltransferase (metabolism)
  • Zebrafish (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: